News and breakthroughs in tissue analysis, biomarkers, and pathology technology.
Flagship Biosciences Provides Analytically Validated Tools to Assist in the Analysis of Summit’s PhaseOut DMD Clinical Trial
CLSI compliant analytically validated cTA™ tools for 2 duplex IHC assays presented at the 22nd annual meeting of the World Muscle Society St. Malo, France,
Flagship Biosciences to Present at the Next Generation Dx Summit
Get the Whole Picture with both Content and Context August 9, 2017 – Westminster, CO – Flagship Biosciences, the leading partner for drug developers investigating
Flagship Biosciences’ support of Summit Therapeutics highlighted at the 2017 Needham Healthcare Conference
Glyn Edwards, CEO of Summit Therapeutics, plc and speaker at the Needham Healthcare Conference, highlighted the work that Flagship Biosciences is doing to support automated
Flagship Biosciences to Demonstrate Benefits of Computational Tissue Analysis for Clinical Pipeline Decisions at ASCO
The benefits of increased confidence and clarity for clinical trial decisions will be presented by Flagship’s team at the Annual Meeting of the American Society
Is PD-L1 Harmonization on the Horizon?
Dr. Joseph Krueger, Flagship Bioscience’s Chief Scientific Officer, was recently interviewed by BioCentury about cTA™ harmonization or the potential to use one predictive assay to
Flagship Biosciences to present quantitative tissue-based data on five clinical trial and immuno-oncology topics at AACR
Flagship Biosciences’ Computational Tissue Analysis (cTA™) and decision support platform featured in five scientific poster presentations at the American Association for Cancer Research Annual Meeting,
